Saverna Therapeutics

[On Demand]
Saverna Therapeutics is a drug discovery company founded in 2017 by former Novartis senior scientists to develop RNA-targeting small molecule drugs to combat diseases with an unmet clinical need. The team developed an innovative drug discovery platform that combines fragment-based screening, nuclear magnetic resonance spectroscopy, and machine learning allowing time- and cost-efficient discovery of promising small molecule drugs selectively targeting specific microRNAs (miRNAs). Saverna’s first development pipeline asset is a small molecule inhibitor of miR-155, a major RNA-based contributor to the development of Scleroderma
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Lead compound for autoimmune diseases
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Saverna Therapeutics